Research Article
Year 2023,
Volume: 5 Issue: 3, 455 - 9, 18.09.2023
Abstract
References
- Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplantation. 2013;48:537-43.
- Ozdemir ZN, Bozdağ SC. Graft failure after allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci. 2018;57:163-7.
- Schneidawind C, Hagmaier V, Faul C, et al. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. J Annals of Hematol. 2018;97:2491-500.
- Thanarajasingam G, Kim HT, Cutler C, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell ransplantation. J Biology of Blood. 2013;19:1713-8.
- Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. Jama Oncol. 2018;4:1245-53.
- Ruutu T, De Wreede L, Van Biezen A, et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant. 2015;50:1542-50.
- Weisdorf DJBp. The role of second transplants for leukemia. Best Pract Res Clin Haematol. 2016;29:359-64.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649-56.
- Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (hct)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. 2005;106:2912-9.
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel. Blood. 2017;129:424-47.
- Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628-33.
- Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute gvhd international consortium. Biol Blood Marrow Transplant. 2016;22:4-10.
- Pavletic SZ, Vogelsang GB, Lee SJ. 2014 national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: preface to the series. Biol Blood Marrow Transplant. 2015;21:387-8.
- Hosing C, Saliba R, Shahjahan M, et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. 2005;36:157-62.
- Poon L, Bassett Jr R, Rondon G, et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013;48:666-70.
- Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the european cooperative group for blood and marrow transplantation. J Clin Oncol. 2001;19:3675-84.
- Shaw B, Mufti G, Mackinnon S, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant. 2008;42:783-9.
- Christopeit M, Kuss O, Finke J, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31:3259-71.
- Gorgeis J, Zhang X, Connor K, et al. T cell–replete hla haploidentical donor transplantation with post-transplant cyclophosphamide is an effective salvage for patients relapsing after an hla-matched related or matched unrelated donor transplantation. Biol Blood Marrow Transplant. 2016;22:1861-6.
- Tischer J, Engel N, Fritsch S, et al. Second haematopoietic sct using hla-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplant. 2014;49:895-901.
- Orti G, Sanz J, Bermudez A, et al. Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the grupo español de trasplante hematopoyetico. Biol Blood Marrow Transplant. 2016;22:584-8.
- Michallet M, Tanguy M, Socie G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the société française de greffe de moelle (sfgm). Br J Haematol. 2000;108:400-7.
- Schmid C, Labopin M, Nagler A, et al. Treatment, risk factors, and outcome of adults with relapsed aml after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119:1599-606.
- Hazar V, Karasu GT, Uygun V, et al. Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the turkish bone marrow transplantation study group. Leuk Lymphoma. 2020;61:1465-74.
Year 2023,
Volume: 5 Issue: 3, 455 - 9, 18.09.2023
Abstract
Aim: It is known that the prognosis of acute leukemia patients who relapse after the first allogeneic stem cell transplantation (ASCT) is dismal. Our goal was to assess the value of a second allogeneic stem cell transplant in acute leukemia patients who experienced post-transplant recurrence.
Material and Methods: We retrospectively reviewed data from 29 patients with relapsing acute leukemia who underwent a second ASCT. Nineteen patients with acute myeloid leukemia and ten patients with acute lymphoblastic leukemia were included in the study.
Results: Ten AML patients and 10 ALL patients were included in the study. Most patients (62%) were in remission before the second transplantation. The median time between the first and second ASCT was 11.9 months (3.1-42 months). Complete remission (CR) was achieved after the second ASCT in 21 (72%) patients, and 11 (52%) patients relapsed after the second ASCT. During this analysis, six patients (21%) were alive and in remission. Relapse of the disease was the leading cause of mortality. After the second ASCT, overall survival (OS) was 6.34 months, and leukemia-free survival (LFS) was 13.8 months.
Conclusion: For patients with acute leukemia who relapsed after the first ASCT, a second ASCT is a good option and can keep patients alive.
References
- Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplantation. 2013;48:537-43.
- Ozdemir ZN, Bozdağ SC. Graft failure after allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci. 2018;57:163-7.
- Schneidawind C, Hagmaier V, Faul C, et al. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. J Annals of Hematol. 2018;97:2491-500.
- Thanarajasingam G, Kim HT, Cutler C, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell ransplantation. J Biology of Blood. 2013;19:1713-8.
- Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. Jama Oncol. 2018;4:1245-53.
- Ruutu T, De Wreede L, Van Biezen A, et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant. 2015;50:1542-50.
- Weisdorf DJBp. The role of second transplants for leukemia. Best Pract Res Clin Haematol. 2016;29:359-64.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649-56.
- Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (hct)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. 2005;106:2912-9.
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of aml in adults: 2017 eln recommendations from an international expert panel. Blood. 2017;129:424-47.
- Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628-33.
- Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute gvhd international consortium. Biol Blood Marrow Transplant. 2016;22:4-10.
- Pavletic SZ, Vogelsang GB, Lee SJ. 2014 national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: preface to the series. Biol Blood Marrow Transplant. 2015;21:387-8.
- Hosing C, Saliba R, Shahjahan M, et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. 2005;36:157-62.
- Poon L, Bassett Jr R, Rondon G, et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013;48:666-70.
- Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the european cooperative group for blood and marrow transplantation. J Clin Oncol. 2001;19:3675-84.
- Shaw B, Mufti G, Mackinnon S, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant. 2008;42:783-9.
- Christopeit M, Kuss O, Finke J, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31:3259-71.
- Gorgeis J, Zhang X, Connor K, et al. T cell–replete hla haploidentical donor transplantation with post-transplant cyclophosphamide is an effective salvage for patients relapsing after an hla-matched related or matched unrelated donor transplantation. Biol Blood Marrow Transplant. 2016;22:1861-6.
- Tischer J, Engel N, Fritsch S, et al. Second haematopoietic sct using hla-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplant. 2014;49:895-901.
- Orti G, Sanz J, Bermudez A, et al. Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the grupo español de trasplante hematopoyetico. Biol Blood Marrow Transplant. 2016;22:584-8.
- Michallet M, Tanguy M, Socie G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the société française de greffe de moelle (sfgm). Br J Haematol. 2000;108:400-7.
- Schmid C, Labopin M, Nagler A, et al. Treatment, risk factors, and outcome of adults with relapsed aml after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119:1599-606.
- Hazar V, Karasu GT, Uygun V, et al. Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the turkish bone marrow transplantation study group. Leuk Lymphoma. 2020;61:1465-74.
There are 24 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Original Articles |
| Authors | |
| Early Pub Date | May 25, 2023 |
| Publication Date | September 18, 2023 |
| Acceptance Date | May 4, 2023 |
| Published in Issue | Year 2023 Volume: 5 Issue: 3 |
Chief Editors
Assoc. Prof. Zülal Öner
Address: İzmir Bakırçay University, Department of Anatomy, İzmir, Türkiye
Assoc. Prof. Deniz Şenol
Address: Düzce University, Department of Anatomy, Düzce, Türkiye
E-mail: medrecsjournal@gmail.com
Publisher:
Medical Records Association (Tıbbi Kayıtlar Derneği)
Address: Düzce / Türkiye
Publication Support:
Effect Publishing & Agency
Phone: + 90 (553) 610 67 80
E-mail: info@effectpublishing.com